NASDAQ:ANGO - AngioDynamics Stock Price, News & Analysis

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) posted its earnings results on Wednesday, July, 10th. The medical instruments supplier reported $0.25 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.26 by $0.01. The medical instruments supplier earned $96.30 million during the quarter, compared to analyst estimates of $92.34 million. AngioDynamics had a return on equity of 5.58% and a net margin of 17.06%. The company's revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the business posted $0.20 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Thursday, September 26th 2019. View Earnings Estimates for AngioDynamics.

AngioDynamics updated its FY20 earnings guidance on Wednesday, July, 10th. The company provided earnings per share guidance of $0.25-0.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.90 million.

1 brokers have issued 12-month price objectives for AngioDynamics' shares. Their forecasts range from $23.00 to $23.00. On average, they anticipate AngioDynamics' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 25.5% from the stock's current price. View Analyst Price Targets for AngioDynamics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AngioDynamics.

Media headlines about ANGO stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AngioDynamics earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for AngioDynamics.

AngioDynamics saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 1,279,100 shares, an increase of 8.5% from the June 30th total of 1,178,600 shares. Based on an average daily trading volume, of 208,100 shares, the days-to-cover ratio is presently 6.1 days. Approximately 3.5% of the company's shares are short sold. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Nevro (NVRO), Glaukos (GKOS), Merit Medical Systems (MMSI), Cardiovascular Systems (CSII), Irhythm Technologies (IRTC), Atrion (ATRI), Silk Road Medical (SILK), Shockwave Medical (SWAV), AtriCure (ATRC), Orthofix Medical (OFIX), Cryolife (CRY), Axonics Modulation Technologies (AXNX), Tactile Systems Technology (TCMD), Luminex (LMNX) and Anika Therapeutics (ANIK).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Oasis Petroleum (OAS), Baidu (BIDU), Amicus Therapeutics (FOLD), Halozyme Therapeutics (HALO), Intel (INTC), Mattel (MAT), Chesapeake Energy (CHK), Centurylink (CTL) and Entercom Communications (ETM).

AngioDynamics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.72%), Victory Capital Management Inc. (10.12%), Vanguard Group Inc. (6.16%), Janus Henderson Group PLC (3.28%), Janus Henderson Group PLC (3.28%) and Northern Trust Corp (3.16%). Company insiders that own AngioDynamics stock include Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, JPMorgan Chase & Co., THB Asset Management, Renaissance Technologies LLC, Invesco Ltd., AXA, Janus Henderson Group PLC and Janus Henderson Group PLC. Company insiders that have sold AngioDynamics company stock in the last year include Kevin J Gould and Michael Greiner. View Insider Buying and Selling for AngioDynamics.

ANGO stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Systematic Financial Management LP, Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, Marshall Wace North America L.P., BlackRock Inc., Morgan Stanley and Natixis Advisors L.P.. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $18.32.

AngioDynamics has a market capitalization of $682.91 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]